// App-Quantinova.ai

: The Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL: Updated Results from the DUO Crossover Extension Study

Researchers

Presenter

  • Matthew S. Davids

Principal Investigators

  • Bryone J. Kuss

  • Peter Hillmen

  • Marco Montillo

  • James Essell

  • Nicole Lamanna

  • Zsolt Nagy

  • Constantine S. Tam

  • Stephan Stilgenbauer

  • Paolo Ghia

  • Julio Delgado

  • NgocDiep Le

  • Stephanie Lustgarten

  • David T. Weaver

  • Ulrich Jaeger

Medical Centers

  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

  • Department of Medical Imaging, Flinders Medical Centre and Flinders University, Bedford Park, Australia

  • St. James's University Hospital, Leeds, United Kingdom

  • Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milano, Italy

  • Oncology Hematology Care Inc., Cincinnati, OH

  • Hematology/Oncology Division, Columbia University Medical Center, New York, NY

  • First Department of Internal Medicine, Semmelweis University, Budapest, Hungary

  • St Vincent's Hospital and University of Melbourne, Peter MacCallum Cancer Center, Melbourne, Australia

  • Department of Internal Medicine, University Hospital of Ulm, Ulm, Germany

  • Fondazione Centro San Raffaele, Milan, Italy

  • Servicio de Hepatología. Hospital Clinic, Barcelona, Spain

  • Verastem Oncology, Needham, MA

  • Dept. of Medicine I, Division of Hematology and Hemostaseology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria

Locations

  • United States

  • Australia

  • United Kingdom

  • Italy

  • Hungary

  • Germany

  • Spain

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • ofatumumab Intravenous

  • Duvelisib

Outcome

  • N/A

Study Design

  • Cross Over

Phase

  • III

Study Id's

  • NCT02004522

  • NCT02049515

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved